Short Courses*
SUNDAY, APRIL 24 (10:00am – 1:00pm)
Registration: 9:00am-5:00pm
SC2: Bioanalytical Considerations of Multi-Domain Biotherapeutics: Preclinical and Clinical Development - Detailed Agenda
Carol Gleason, MS, Principal Biostatistician, Bristol-Myers Squibb Co.
Yanchen Zhou, Ph.D., Scientist, Amgen Inc.
Darshana Jani, M.S., Senior Manager, Pfizer, Inc.
Priya Sriraman, Ph.D, Senior Principal Scientist, Non Clinical Safety, Celgene
Shannon D. Chilewski, MSc, Research Scientist II, Analytical and Bioanalytical Development, Bristol-Myers Squibb
SC3: Antibody Humanization via One Hot Homology Model Workshop (Hands-On) - Detailed Agenda
Vinodh B. Kurella, Ph.D., Senior Scientist, Molecular Engineering Unit, Intrexon Corp.
SC4: Translational Considerations for Development of Monoclonal Antibodies: Focus on Early Discovery (Part I) - Detailed Agenda
Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis Pharmaceuticals
Randall Brezski, Ph.D., Scientist, Antibody Engineering, Genentech
Enrique Escandon, Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck Research Laboratories
Vaishnavi Ganti, Ph.D., Senior Scientist, Biologics Discovery-DMPK, Merck Research Laboratories
Scott L. Klakamp, Ph.D., Vice President, Chemistry and Biochemistry, Bioptix
Mohammad Tabrizi, Ph.D., Head, Director & Senior Fellow, PKPD, Merck
SUNDAY, APRIL 24 (2:00 – 5:00pm)
SC6: In silico Immunogenicity Predictions (Hands-On) Workshop - Detailed Agenda
Vinodh B. Kurella, Ph.D., Senior Scientist, Molecular Engineering Unit, Intrexon Corp.
SC7: Translational Considerations for Development of Monoclonal Antibodies: Focus on Nonclinical Development to Clinic (Part II) - Detailed Agenda
Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis Pharmaceuticals
Randall Brezski, Ph.D., Scientist, Antibody Engineering, Genentech
Enrique Escandon, Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck Research Laboratories
Vaishnavi Ganti, Ph.D., Senior Scientist, Biologics Discovery-DMPK, Merck Research Laboratories
Scott L. Klakamp, Ph.D., Vice President, Chemistry and Biochemistry, Bioptix
Mohammad Tabrizi, Ph.D., Head, Director & Senior Fellow, PKPD, Merck
TUESDAY, APRIL 26 (6:00pm-8:00pm)
DINNER
SC8: Next-Generation Sequencing of Antibody Libraries: Details on Experimental and Bioinformatic Methods - Detailed Agenda
Sai Reddy, Ph.D., Assistant Professor, Biosystems Science and Engineering, ETH Zurich, Switzerland
SC9: Overcoming the Challenges of Immunogenicity Assessment - Detailed Agenda
Jim McNally, Ph.D., Associate Director, PDM Immunogenicity Expert, EMD Serono
Valerie Theobald, Ph.D., Director, Bioanalytical Development, Shire
SC10: Analyzing and Rationalizing Protein-Protein Interactions - Detailed Agenda
Nels Thorsteinson, Scientific Services Manager, Biologics, Chemical Computing Group
Alain Ajamian, Ph.D., Director, Chemical Computing Group
THURSDAY, APRIL 28 (5:45pm-7:45pm)
DINNER
SC11: Clinical Prospects of Cancer Immunotherapy - Detailed Agenda
Gaurav Goel, M.D., Assistant Professor, Division of Medical Oncology, Medicine, University of Kentucky Markey Cancer Center
Weijing Sun, M.D., FACP, Professor, Medicine; Director, GI Cancers Section of Hematology-Oncology; Co-Director, GI Cancer Center of Excellence, Medicine/Hematology-Oncology, University of Pittsburgh School of Medicine
SC12: Strategic Bioassay Design and Analysis - Detailed Agenda
Liming Shi, MS, MA, Senior Group Leader, Bioassay Development, Hospira, a Pfizer Company
SC13: Critical Considerations for the Design and Development of Antibody-Drug Conjugates - Detailed Agenda
Mohammad Tabrizi, Ph.D., Head, Director & Senior Fellow, PKPD, Merck
Isabel Figueroa, Ph.D., Scientist, PTPK Department, Genentech
Shawn Owen, Ph.D., Assistant Professor, Pharmaceutical Chemistry, University of Utah
*Separate Registration Required